Mimotopes to produce peptides for Invitrogen
Thursday, 06 October, 2005
Mimotopes, a wholly owned subsidiary of PharmAust (ASX:PAA), is to supply California-based life science technology group Invitrogen Corporation (NASDAQ:IVGN) with custom pre-clinical peptides for Invitrogen's customers worldwide.
The preferred outsourcing agreement is on a 12-month rolling term. An initial standing order of custom peptides has been placed valued at between AUD$130,000 and AUD$200,000 per month. Mimotopes expects to generate initial revenues of over AUD$1.5 million per annum from the contract.
With a market capitalisation of US$4 billion, Invitrogen provides technologies for disease research, drug discovery and commercial bioproduction to research institutions, pharmaceuticals and biotechnology companies.
Link between oestrogen and heart health found in women
Scientists found that oestrogen helps increase the ANXA1 protein, and when ANXA1 is missing, the...
Frequent nightmares accelerate aging, increase risk of death
Nghtmares independently predict faster biological aging and earlier mortality — even after...
Cardiac organoids bring hope for treating heart disease
Australian scientists have developed lab-grown, three-dimensional heart tissues known as cardiac...
